New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - Yale University School of Medicine, New Haven, CT, USA

Silvio Inzucchi summarises recent developments in treatment of type 2 diabetes. Some new agents yield clear CV event risk reduction, while older glucose-lowering medication only had a moderate effect on CV events.

Educational information

Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA

Disclosures

Silvio E. Inzucchi, MD - Professor of Medicine, Yale University School of Medicine, New Haven, CT, USA

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.